ProtoKinetix Inc PKTX

target price

[lindbeck]

On their website they post a $1.32 target price. Grosvenor Financial Partners LLC Initial Report 9/26/07. Here, I'll paste it for you. VALUATION ProtoKinetix is a unique situation for the high risk, small cap, speculative investor seeking a company with dynamic growth potential. Since inception in 1999, the Company has primarily focused on theoretical science, but is in now the process of redirecting its major efforts to the practical side of its business. After years of research, ProtoKinetix has been granted significant patent coverage that will permit it to apply the dynamic interlocking molecular structure of AAGP™ to provide a profound enhancement to a vast array of existing biotechnology regimens. Certainly ProtoKinetix faces numerous challenges, obstacles and risks at this stage of the product cycle. We believe these risks can be managed to provide a balanced approach for the benefit of shareholders and strategic partners. ProtoKinetix maintains a highly efficient cost management structure in all of its endeavors. As a result management can mitigate some of the risk associated with development of products that can take several years to reach complete development of required testing and FDA approval.At this juncture, it is virtually impossible to construct a sales model for various potential products, because of the presently nacent aspect of the Company's shift into applications with revenue prospects from research on projects that have in the past consumed capital. We think that present valuation may to a large degree be derived from the stock's past price history, however. In 2004 the annual high for PKTX stock was over $1.50 a share, and in 2005 the annual high was over $1.20 per share. We calculate that an equivalent price today to account for the significant subsequent equity dilution would be about $1.02 a share. We think that as soon as the Company's skin-care prospects become more defined that the market will start to discount a revenue stream, and perhaps add another $0.30 to its share price. From this analysis we feel comfortable in projecting a future price of $1.32 a share. Certainly it appears that ProtoKinetix is very undervalued relative it both own past valuation and its greatly enhanced future prospects.